# A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

> **NCT06522737** · PHASE3 · RECRUITING · sponsor: **SecuraBio** · enrollment: 124 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Gemcitabine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06522737
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2028-02
- **Final completion:** 2028-12
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06522737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06522737, "A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06522737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*